Avacincaptad pegol


Avacincaptad pegol

Drug updated on 4/16/2024

Dosage FormInjection (intravitreal; 20 mg/mL in a single-dose vial)
Drug ClassComplement inhibitors
Ongoing and
Completed Studies


  • Indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Avacincaptad pegol (Izervay) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It is beneficial in reducing GA lesion growth, especially in participants with extrafoveal or juxtafoveal GA, but it does not significantly improve best-corrected visual acuity.
  • Two studies provided information about Izervay's safety and effectiveness compared to other treatments like Lampalizumab and Pegcetacoplan.
  • Izervay demonstrated higher reduction rates, between 25.6% to 30.5%, in GA lesion growth compared to Lampalizumab and Pegcetacoplan, which did not significantly impact this parameter.
  • The safety profile of Izervay did not report any cases of endophthalmitis, suggesting a potentially lower risk compared to other intravitreal treatments like Lampalizumab and Pegcetacoplan, which presented small but notable risks.
  • All three treatments, including Izervay, showed an increased risk for the development of macular neovascularization, indicating a concern for worsening AMD status; however, the evidence supporting this was of low certainty for all treatments.
  • There was little difference in systemic adverse events among these treatments compared with sham procedures, but ocular treatment-emergent adverse effects occurred more frequently, especially due to new onset neovascular AMD resulting from complement inhibition.

Product Monograph / Prescribing Information

Document TitleYearSource
Izervay (avacincaptad pegol) Prescribing Information.2023IVERIC Bio, Inc., Cranbury, NJ

Systematic Reviews / Meta-Analyses